Paper Details

  1. Home
  2. Paper Details

Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma.

Author: GowerRichard, LeidyNancy Kline, SchmierJordana

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the impact of mometasone furoate dry powder inhaler (MF DPI) on health-related quality of life (HRQL) in patients with severe persistent asthma. The results showed that MF DPI significantly improved HRQL, particularly in the physical domain, and this improvement was maintained during the open-label extension period.
Paper Details　
Original Abstract of the Article :
Severe persistent asthma can have a substantial impact on a patient's health-related quality of life (HRQL), both as a result of symptoms and from side effects of treatment. The HRQL impact of two doses (400 and 800 microg twice daily) of mometasone furoate dry powder inhaler (MF DPI) was compared w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1081/jas-120018708

データ提供：米国国立医学図書館（NLM）

Reduction in Oral Corticosteroid Use with Mometasone Furoate Dry Powder Inhaler Improves Health-Related Quality of Life in Patients with Severe Persistent Asthma

This study addresses the significant impact of severe persistent asthma on health-related quality of life (HRQL). The study compared the effects of two doses of mometasone furoate dry powder inhaler (MF DPI) to placebo in patients with severe persistent asthma who were previously maintained on oral corticosteroids. The study found that MF DPI was associated with a significant improvement in HRQL, particularly in the physical domain, and a reduction in oral corticosteroid (OCS) use.

Improving HRQL in Severe Persistent Asthma

The research indicates that MF DPI can improve HRQL and reduce OCS use in patients with severe persistent asthma. This suggests a potential benefit for patients in managing their asthma symptoms and enhancing their overall well-being.

Health and Lifestyle Implications

This study offers hope for individuals with severe persistent asthma, highlighting a potential treatment option that can improve HRQL and reduce reliance on OCS. As with any medication, it's essential to discuss with a healthcare provider the potential benefits and risks of MF DPI, considering individual needs and medical history.

Dr.Camel's Conclusion

Think of severe persistent asthma as a sandstorm constantly swirling around, impacting quality of life. MF DPI, like a refreshing desert breeze, can help clear the storm and improve the well-being of patients with severe persistent asthma. This research shows that MF DPI might be a useful tool for managing asthma symptoms and reducing the need for oral corticosteroids, but always consult with a doctor before embarking on any new treatment journey.

Date :
  1. Date Completed 2003-08-26
  2. Date Revised 2019-09-22
Further Info :

Pubmed ID

12870834

DOI: Digital Object Identifier

10.1081/jas-120018708

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.